Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
10.1016/j.jtho.2019.08.1166
dc.identifier.other
dc.description.volume
14
dc.description.issue
10
S
S
Publisher
DOI
10.1016/j.jtho.2019.08.1166